Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on J&J Sealed Clinical Studies Request

The firm is currently offering Risperdal lawsuit evaluations to those who allege that they suffered from the drug’s alleged side effects.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
The firm is currently offering Risperdal lawsuit evaluations to those who allege that they suffered from the drug’s alleged side effects.

The firm is currently offering Risperdal lawsuit evaluations to those who allege that they suffered from the drug’s alleged side effects.

It seems the plaintiffs’ attorneys asked to have the documents unsealed to shed light on the data from specific clinical trials.

(PRWEB) December 04, 2013

Drug maker Johnson & Johnson has requested that a Pennsylvania state judge keep sealed documents pertaining to results of clinical studies involving antipsychotic medication Risperdal, according to court documents. The Rottenstein Law Group LLP, which represents clients in Risperdal lawsuits, discusses the nature of the request and highlights recent news involving a multibillion dollar Risperdal settlement.

The request is related to an order in 2011 that sealed the results, and Johnson & Johnson and subsidiary Janssen Pharmaceuticals assert that the documents are not public records, thus precluding the obligation to provide them to plaintiffs, according to court documents (In re: Risperdal Litigation; Case No. 100300296, Philadelphia Court of Common Pleas). J&J argues that because the documents are generated for researchers and regulators, and not for the general public, there is no reason to unseal them, according to court documents.

“A recent Risperdal settlement involved criminal and civil fines levied against Johnson & Johnson because of the drug’s serious alleged side effects, some of which were identified in clinical studies,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “It seems the plaintiffs’ attorneys asked to have the documents unsealed to shed light on the data from specific clinical trials.”

J&J agreed to pay $2.2 billion in civil and criminal fines to settle claims it improperly marketed the antipsychotic medication Risperdal to children, seniors and people with developmental disabilities, according to a Nov. 4 New York Times story.* The United States Department of Justice announced the settlement, which also includes heart-failure drug Natrecor and the antipsychotic Invega.

The federal government alleges that J&J marketed the drug to high-risk groups between 1999 and 2005, the story said, adding that part of the settlement includes J&J’s pleading guilty to a criminal misdemeanor for its role in promotion of the drug to those groups.

Risperdal has been shown to almost double the risk of heart disease and pneumonia in elderly dementia patients, according to the U.S. Food and Drug Administration.**

The Rottenstein Law Group LLP encourages those who believe they or their loved ones have suffered from the alleged side effects of Risperdal to visit the firm's website to learn about Risperdal lawsuits and side effects.

*nytimes.com/2013/11/05/business/johnson-johnson-to-settle-risperdal-improper-marketing-case.html

**http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm152291.htm
About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
plus.google.com/106070664376281033016